MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS

被引：0
|
作者：
Wild, L. [1 ]
Forster, L. [1 ]
机构：
[1] Double Helix Consulting, London, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.566
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A335 / A336
页数：2
相关论文
共 50 条
  • [21] Focus shifts in the Hungarian reimbursement system Funding of orphan medicinal products for rare disease patients in Hungary: Financing of orphan medicines
    Szegedi Marta
    Maria Molnar Judit
    Boncz Imre
    Kosztolanyi Gyorgy
    ORVOSI HETILAP, 2014, 155 (44) : 1735 - 1741
  • [22] PRICING AND REIMBURSEMENT ENVIRONMENT FOR A BIOLOGIC OBTAINING A LICENCE IN A SECOND INDICATION IN KEY EUROPEAN COUNTRIES
    Ling, C. S.
    Balp, M. M.
    Bjoerk, B.
    Quijano, M.
    Heyes, A. E.
    VALUE IN HEALTH, 2014, 17 (07) : A429 - A429
  • [23] Crowd Funding for Orphan Drugs: The Case of Baby Pia
    Pinxten, Wim
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [24] TOP 20 ORPHAN DRUGS AVAILABILITY, PRICING AND REIMBURSEMENT IN SLOVAKIA: 2005-2012 REVIEW
    Babela, R.
    Uraz, V
    Babelova, O.
    Slezakova, Z.
    VALUE IN HEALTH, 2014, 17 (07) : A540 - A541
  • [25] Variables affecting pricing of orphan drugs: the Italian case
    Jommi, Claudio
    Listorti, Elisabetta
    Villa, Federico
    Ghislandi, Simone
    Genazzani, Armando
    Cangini, Agnese
    Trotta, Francesco
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [26] Variables affecting pricing of orphan drugs: the Italian case
    Claudio Jommi
    Elisabetta Listorti
    Federico Villa
    Simone Ghislandi
    Armando Genazzani
    Agnese Cangini
    Francesco Trotta
    Orphanet Journal of Rare Diseases, 16
  • [27] VARIABLES AFFECTING PRICING OF ORPHAN DRUGS: THE ITALIAN CASE
    Jommi, C.
    Listorti, E.
    Villa, F.
    Ghislandi, S.
    Genazzani, A.
    Cangini, A.
    Trotta, F.
    VALUE IN HEALTH, 2022, 25 (01) : S148 - S148
  • [28] From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
    Elvio Emanuele Rossini
    Carlotta Galeone
    Chiara Lucchetti
    Claudio Jommi
    PharmacoEconomics - Open, 2024, 8 : 251 - 261
  • [29] HOW CAN PHARMA INDUSTRY PREPARE ITSELF FOR THE CHANGING PRICING AND REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS IN EU?
    Mukku, S.
    Pang, F.
    Mcconkey, D.
    VALUE IN HEALTH, 2011, 14 (07) : A357 - A357
  • [30] MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
    Vollmer, L.
    Prada, M.
    Benazet, F.
    Berard, I
    Lopez, N.
    Guterres, S.
    Walzer, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
12345